Curative Biotechnology (Curative Biotechnology) EBIT : $-3.80 Mil (TTM As of Mar. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Curative Biotechnology EBIT?

Curative Biotechnology's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2023 was $-0.66 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2023 was $-3.80 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Curative Biotechnology's annualized ROC % for the quarter that ended in Mar. 2023 was -80.23%. Curative Biotechnology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was -43,666.67%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Curative Biotechnology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was -22.37%.

Curative Biotechnology EBIT Historical Data

The historical data trend for Curative Biotechnology's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curative Biotechnology EBIT Chart

Curative Biotechnology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT

Get a 7-Day Free Trial

-0.01

0.35

-4.64

-5.16

-4.44

Curative Biotechnology Quarterly Data
	Dec16	Dec17	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
EBIT	Get a 7-Day Free Trial															-1.29	-0.96	-1.08	-1.11	-0.66

Competitive Comparison of Curative Biotechnology's EBIT

For the Biotechnology subindustry, Curative Biotechnology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curative Biotechnology's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curative Biotechnology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Curative Biotechnology's EV-to-EBIT falls into.

Curative Biotechnology EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.80 Mil.

Curative Biotechnology (OTCPK:CUBT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Curative Biotechnology's annualized ROC % for the quarter that ended in Mar. 2023 is calculated as:

	ROC % (Q: Mar. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2022 )	+	Invested Capital (Q: Mar. 2023 ))	/ count )
=	-2.62 * ( 1 - 0% )	/	( (3.112	+	3.419)	/ 2 )
=	-2.62	/	3.2655
=	-80.23 %

where

	Invested Capital		(Q: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2.089	-	3.395	-	( 0.059	-	max(0, 4.487	-	0.069	+	0.059	))
=	3.112

	Invested Capital		(Q: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2.132	-	3.937	-	( 0.098	-	max(0, 5.332	-	0.108	+	0.098	))
=	3.419

Note: The Operating Income data used here is four times the quarterly (Mar. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Curative Biotechnology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2022		Q: Mar. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-2.62	/	( ( (0.006 + max(-3.406, 0))	+	(0.006 + max(-3.953, 0)) )	/	2 )
=	-2.62	/	( ( 0.006	+	0.006 )	/	2 )
=	-2.62	/	0.006
=	-43,666.67 %

where Working Capital is:

	Working Capital		(Q: Dec. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.01)	-	(3.395	+	0	+	0.021)
=	-3.406

	Working Capital		(Q: Mar. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.01)	-	(3.937	+	0	+	0.026)
=	-3.953

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Curative Biotechnology's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2023 )
	=	-3.801	/	16.988
	=	-22.37 %

Curative Biotechnology EBIT Related Terms

Thank you for viewing the detailed overview of Curative Biotechnology's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Curative Biotechnology (Curative Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curative Biotechnology Inc (OTCPK:CUBT) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

1825 NW Corporate Boulevard, Suite 110, Boca Raton, FL, USA, 33431

Website

https://www.curativebiotech.com

Curative Biotechnology Inc is a development-stage biomedical company focusing on novel treatments for rare diseases. The company currently has ongoing programs in three therapeutic areas: Infectious Disease, Neuro-Oncology, and Degenerative Eye Disease.